MedTrace Logo

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-22

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

Interventions

DRUG

ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection

Sponsors & Collaborators

  • Oruka Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-19
Primary Completion
2027-10-31
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07474792 on ClinicalTrials.gov